SenzaGen at a glance.

SV EN

SenzaGen’s vision is to protect and advance human health through innovative technology that replaces animal testing.

Vision and goal

The SenzaGen Group is a fast-growing leader in the field of non-animal testing. Through ground-breaking innovations and scientific expertise that better reflect human biology, the Group advances and protects human health while contributing to the replacement of animal testing.

GARD skin and respiratory sensitization testing

CEO comment

Building the future of non-animal testing

“We are working toward a vision to help the leading companies of the world transition from animal testing to alternative methods with better relevance and performance for humans. This is an issue that is of the upmost importance for both today and tomorrow’s society, and as a leader of advanced test systems our company has the prospects to continue growing for many years to come.

Our OECD-approved test, high-tech solutions and advisory services in a market that is continuing to grow from technological, regulatory and ethical drivers give us a very favorable position for continuing high growth.”

LATEST PRESENTATIONS

Growth strategy

SenzaGen’s growth plan extends to 2030 and focuses on strategic initiatives that drive profitable growth within non-animal testing. The plan is divided into three phases, together outlining the company’s path toward long-term, organic expansion.
Growth plan

  • Breakeven

    The current phase focuses on reaching breakeven through continued growth combined with strict cost control.

  • Accelerated growth

    This phase is driven by strategic initiatives expected to deliver significant revenue impact and improved profitability.

  • Scale-up:

    The final phase encompasses expansion into new markets and the launch of new test methods. Growth and profitability are expected to stabilize at high levels.

In addition to the organic growth plan, strategic acquisitions may complement and strengthen growth across all phases.

Strategic initiatives

  • Expand market reach through an optimized commercial model

  • Establish GARD® as an industry standard in medical devices

  • Advance GARD® through regulatory approvals and technology upgrades

  • Scale with innovations

2018-2026

Financial Performance

FINANCIAL REPORTS

The growing market is undergoing a paradigm shift

The in vitro toxicology testing market is global and growing strongly. SenzaGen estimates its serviceable addressable market (SAM) at approximately SEK 5.8 billion (USD 0.5 billion).

Major companies from large industries

A paradigm shift is taking place in the market. Companies worldwide are transitioning from animal testing to non-animal testing, and customers come from several industries, including cosmetics, chemicals, medical device, pharmaceuticals, and nutrition/food additives. The customer base consists of leading multinational companies, primarily based in Europe and North America.

Expertise in Toxicology, Pharmacology and Regulatory Compliance

Pre-clinical efficacy testing

VitroScreen

VitroScreen, acquired by SenzaGen in 2021, is a Milan-based expert in non-animal testing with over 20 years of experience in 3D human tissue models. The company focuses on preclinical efficacy testing and has developed the proprietary organoid platform VitroScreenORA®. It also provides complementary toxicological safety services.

Through VitroScreen, the SenzaGen Group expands its expertise in advanced human tissue models and organoids—supporting early product development with scientifically robust, non-animal methods.

VITROSCREEN
Substance-based Medical Device Services

Toxicology consulting

ToxHub

ToxHub, based in Rome and acquired in 2022, specializes in toxicological risk assessment and regulatory strategy. Founded by experienced toxicologists, it supports sectors including Medical Devices, Pharmaceuticals, Cosmetics, and Chemicals.

ToxHub complements SenzaGen’s testing services by offering expert regulatory guidance from early development to product filing.

TOXHUB

Our contribution to a more sustainable world

SenzaGen helps the world’s leading companies ensure the safety of their products and production environments, while also contributing to a reduction in the use of animal testing.
SUSTAINABILITY

History

  • 2025

    Insourcing of EpiSensA

    Insourcing of EpiSensA for regulatory skin sensitization testing.

  • 2023

    In-sourcing of Cytotoxicity for Medical Devices

    In-sourcing of Cytotoxicity for medical devices. SenzaGen was recognized by Deloitte, which named SenzaGen one of Sweden’s fastest growing technology companies in Sweden Technology Fast 50.

  • 2022

    Acquisition of ToxHub: Toxicology advisory

    OECD approval of GARD®skin. Acquisition of ToxHub, which provides regulatory toxicology and risk assessment services.

  • 2021

    Acquisition of VitroScreen: Efficacy testing. In-sourcing of skin irritation and skin corrosion

    Peter Nählstedt takes office as CEO. New strategy combining organic growth with acquisitions. Acquisition of VitroScreen, which provides preclinical testing. Broadened regulatory test poertfolio via in-sourcing of skin irritation and skin corrosion.

  • 2020

    GARD®skin Dose-Response

    Launch of GARD®skin Dose-Response, a test to define the dose level at which chemicals can cause skin allergies.

  • 2019

    GARD®skin Medical Device

    SenzaGen grows from a research company into a commercial enterprise with a focus on sales. Launch of GARD®skin Medical Device for the medical devices market.

  • 2018

    GARD®air

    Test to determine whether chemicals can cause allergic reactions in the respiratory tract.

  • 2017

    GARD®skin. Listing on Nasdaq First North

    Launch and initial pilot sales of GARD®skin, test to assess whether chemicals can cause allergic reactions on the skin. The company was listed on Nasdaq First North Stockholm.

  • 2014

    Submission of OECD-application

    SenzaGen becomes an operating company and submits an OECD application for the non-animal GARD®skin test for skin allergy.

  • 2013

    Animal ban in EU

    The EU enacts a ban on sales of animal-tested cosmetics.

  • 2010

    SenzaGen was founded

    SenzaGen was founded in 2010 based on many years of research at Lund University. This research has its roots in studies performed at the Department of Immunotechnology under the leadership of Carl Borrebaeck, professor and prefect, and Malin Lindstedt, professor and senior lecturer.

PreviousNext

Subscribe


Prenumerera